CIK 0000715446
- Non-accelerated filer
- Smaller reporting company
Anixa Biosciences Inc
Sign in to watch- Ticker
- ANIX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Oct 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 112622630
- Phone
- +1 408-708-9808
- Business address
- 3150 ALMADEN EXPRESSWAY, SUITE 250, SAN JOSE, CA, 95118
- Former names
- ITUS Corp, COPYTELE INC
- 4 Open-market buy Director bought 87,700 shares at an average $0.16 ($14,391)
- 4 Open-market buy Director bought 70,000 shares at $0.15 ($10,430)
- 4 Open-market buy Director bought 150,000 shares at an average $0.14 ($21,200)
- 4 Open-market buy Director bought 100,000 shares at an average $0.14 ($13,700)
- 4 Open-market buy President and CEO bought 30,000 shares at $0.14 ($4,269)
- 4 Open-market buy Director bought 50,000 shares at an average $0.16 ($8,140)
- 4 Open-market buy Director bought 30,000 shares at an average $0.15 ($4,440)
- 4 Open-market buy Director bought 10,000 shares at an average $0.16 ($1,612)
- 4 Open-market buy Director bought 206,544 shares at an average $0.15 ($30,076)
- 4 Open-market buy Director bought 10,000 shares at $0.13 ($1,270)
- 4 Open-market buy Director bought 155,000 shares at an average $0.14 ($21,173)
- 4 Open-market buy Director bought 245,000 shares at an average $0.10 ($25,220)
- 4 Open-market buy Director bought 223,325 shares at an average $0.11 ($23,909)
- 4 Open-market buy President and CEO bought 100,000 shares at an average $0.11 ($11,105)
- 4 Open-market buy Director bought 110,000 shares at $0.09 ($9,922)
- 4 Open-market buy Director bought 215,258 shares at $0.09 ($20,277)
- 4 Open-market buy Director bought 425,000 shares at an average $0.23 ($97,513)
- 4 Open-market buy Director bought 113,000 shares at $0.08 ($9,040)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
Page 16 of 24 · 471 filings